

0135.03

What is claimed is:

1. An isolated bacteriocin produced by a lactic acid producing bacterial strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30514, NRRL B-30510, NRRL B-30511, and NRRL B-30645.
2. The bacteriocin of claim 1 having an amino acid sequence of SEQ ID NO 1.
3. The bacteriocin of claim 1 having an amino acid sequence of SEQ ID NO 2.
4. The bacteriocin of claim 1 having an amino acid sequence of SEQ ID NO 3.
5. The bacteriocin of claim 1 having an amino acid sequence of SEQ ID NO 4.

0135.03

6. An isolated *Lactobacillus* spp. having the identifying characteristics of a *Lactobacillus* strain selected from the group consisting of NRRL B-30514 and NRRL B-30510.

7. An isolated *Lactobacillus* spp. having the identifying characteristics of NRRL B-30510.

8. An isolated *Lactobacillus salivarius* having the identifying characteristics of NRRL B-30514.

9. An isolated *Enterococcus* strain having the identifying characteristics of an *Enterococcus* strain selected from the group consisting of NRRL B-30645 and NRRL B-30511.

10. An isolated *Enterococcus faecalis* having the identifying characteristics of NRRL B-30645.

11. An isolated *Enterococcus durans* having the identifying characteristics of NRRL B-30511.

0135.03

12. A therapeutic composition comprising:

(a) at least one isolated bacteriocin produced by a lactic acid-producing bacterial strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30514, NRRL B-30510, NRRL B-30645, NRRL B-30511, and mixtures thereof in amount effective to at least reduce levels of colonization by at least one target bacteria; and

(b) a suitable therapeutic carrier.

13. A therapeutic composition comprising:

(a) an isolated bacteriocin produced by a *Lactobacillus salivarius* strain having the identifying characteristics of NRRL B-30514 in amounts effect to at least reduce levels of colonization by at least one target bacteria, and

(b) a suitable therapeutic carrier.

14. The therapeutic composition of claim 12 wherein said bacteriocin has an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 or mixtures thereof.

0135.03

15. The therapeutic composition of claim 14 wherein said bacteriocin has an amino acid sequence of SEQ ID NO 1.

16. The therapeutic composition of claim 14 wherein said bacteriocin has an amino acid sequence of SEQ ID NO 2.

17. The therapeutic composition of claim 14 wherein said bacteriocin has an amino acid sequence of SEQ ID NO 3.

18. The therapeutic composition of claim 14 wherein said bacteriocin has an amino acid sequence of SEQ ID NO 4.

19. A therapeutic composition comprising:

(a) at least one isolated bacteriocin produced by a *Lactobacillus* spp. having the identifying characteristics of NRRL B-30510 in amounts to at least reduce the levels of colonization by at least one target bacteria; and

(b) a therapeutically acceptable carrier.

20. A therapeutic composition comprising:

0135.03

(a) at least one isolated bacteriocin produced by an *Enterococcus durans* having the identifying characteristics of NRRL B-30511 in amounts to at least reduce the levels of colonization by at least one bacteria; and

(b) a therapeutically acceptable carrier.

21. A therapeutic composition comprising:

(a) at least one isolated bacteriocin produced by an *Enterococcus faecalis* having the identifying characteristics of NRRL B-30645 in amounts to at least reduce the levels of colonization by at least one bacteria; and

(b) a therapeutically acceptable carrier.

22. A therapeutic feed for animals comprising:

(a) at least one isolated bacteriocin produced by a lactic acid-producing bacterial strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30514, NRRL B-30510, NRRL B-30511, NRRL B-30645, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria,

0135.03

- (b) a therapeutic carrier, and
- (c) an animal feed.

23. The therapeutic feed of claim 22 wherein said at least one bacteriocin has an amino acid sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, and mixtures thereof.

24. A therapeutic feed for animals comprising:

- (a) a bacteriocin produced by a *Lactobacillus* strain having the identifying characteristics of a *Lactobacillus* strain selected from the group consisting of NRRL B-30510, NRRL B-30514, and mixtures thereof; in amounts effective to at least reduce the levels of colonization by at least one target bacteria,
- (b) a therapeutic carrier, and
- (c) an animal feed.

25. The therapeutic feed of claim 24 wherein said bacteriocin has an amino acid sequence selected from the group consisting of SEQ ID NO 1 and SEQ ID NO 2.

0135.03

26. A therapeutic feed for animals comprising:

(a) at least one isolated bacteriocin produced by an *Enterococcus* strain having the identifying characteristics of an *Enterococcus* strain selected from the group consisting of NRRL B-30511, NRRL B-30645, and mixtures thereof; in amounts effective to at least reduce the levels of colonization by at least one target bacteria,

(b) a therapeutic carrier, and

(c) an animal feed.

27. The therapeutic feed of claim 26 wherein said bacteriocin has an amino acid sequence selected from the group consisting of SEQ ID NO 3 and SEQ ID NO 4.

28. A method for at least reducing the level of colonization by at least one a target bacteria in an animal comprising:

administering to an animal a therapeutic composition comprising at least one bacteriocin produced by a lactic acid-producing bacterial strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30514,

0135.03

NRRL B-30510, NRRL B-30511, NRRL B-30645, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria and a therapeutic carrier.

29. The method of claim 28 wherein said bacteriocin has an amino acid sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, and mixtures thereof.

30. The method of claim 29 wherein said bacteriocin has an amino acid sequence SEQ ID NO 1.

31. The method of claim 29 wherein said bacteriocin has an amino acid sequence SEQ ID NO 2.

32. The method of claim 29 wherein said bacteriocin has an amino acid sequence SEQ ID NO 3.

33. The method of claim 29 wherein said bacteriocin has an amino acid sequence SEQ ID NO 4.



0135.03

34. A method for at least reducing the level of colonization by at least one a target bacteria in an animal comprising:

administering to an animal a therapeutic composition comprising:

(a) at least one bacteriocin produced by a lactic acid-producing bacterial strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30514, NRRL B-30510, NRRL B-30511, NRRL B-30645, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria,

(b) at least one lactic acid-producing bacterial strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30514, NRRL B-30510, NRRL B-30511, NRRL B-30645, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria; and

(c) a therapeutic carrier.